Exocrine Pancreatic Insufficiency Clinical Trials

Find Exocrine Pancreatic Insufficiency Clinical Trials Near You

The Effect of Pancreatin Added to Standard Antihyperglycemic Therapy on Metabolic Control in Patients With Type 2 Diabetes

Status: Recruiting
Location: See location...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Phase 4
SUMMARY

Medications that enhance the incretin effect (GLP-1 receptor agonists, tirzepatide (GIP/GLP-1 receptor agonist) and DPP-4 inhibitors) are used in treatment of patients with type 2 diabetes. GLP-1 agonists and tirzepatide not only effectively lower blood glucose levels but also promote weight loss-primarily by stimulating the satiety center in the central nervous system - and reduce cardiovascular risk. Evidence suggests that oral pancreatin supplementation also enhances the incretin effect by increasing GIP and GLP-1 concentrations, and consequently insulin levels, which translates into a reduction in postprandial glycemia in patients with cystic fibrosis or chronic pancreatitis. In our study we aim to evaluate the impact of pancreatin on the incretin effect and glycemic control in patients with type 2 diabetes without exocrine pancreatic insufficiency.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 35
Maximum Age: 75
Healthy Volunteers: f
View:

• Type 2 diabetes diagnosed for at least 12 months

• Patients treated with oral antihyperglycemic agents and/or insulin as monotherapy or combination therapy

• Age between 35 and 75 years

• HbA1c: 6.5% - 9.0%

Locations
Other Locations
Poland
Department of Internal Medicine, Diabetology and Cardiometabolic Disorders, Faculty of Medical Sciences Zabrze
RECRUITING
Zabrze
Contact Information
Primary
Marta Wróbel, PhD
mwrobel@sum.edu.pl
48606873060
Backup
Paulina Piekarz-Ząbek, MD
k_bielawa@poczta.fm
‭+48 604 223 652‬
Time Frame
Start Date: 2026-08-01
Estimated Completion Date: 2027-12-31
Participants
Target number of participants: 100
Treatments
Experimental: Pancreatin
Participants receiving pancreatin
Placebo_comparator: Control
Participants receiving placebo
Sponsors
Leads: Silesian Centre for Heart Diseases
Collaborators: Medical University of Silesia

This content was sourced from clinicaltrials.gov

Similar Clinical Trials